



SOLVE
ON.

Incyte to Present at the Banc of America Health Care Conference

May 18, 2004

WILMINGTON, Del., May 18, 2004 -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Banc of America Health Care Conference on Thursday, May 20, 2004 at 2:40 p.m. (PT). Paul Friedman, M.D., chief executive officer of Incyte, will provide an overview of the company and discuss its most advanced drug discovery and development programs.

The presentation will be webcast live and can be accessed at: www.incyte.com/webcasts. A replay of the presentation will be available until June 30, 2004.

About Incyte

Incyte Corporation is a Wilmington, Delaware based drug discovery and development company with a growing pipeline of oral small molecule drugs to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset(TM), is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. The company's lead internal compound, INCB3284, is a proprietary, oral CCR2 antagonist in Phase I development that may have therapeutic value in a number of chronic inflammatory diseases. Incyte has several other early drug discovery programs underway and a proteomic information business based in Beverly, Massachusetts.

SOURCE: Incyte Corporation

Incyte Corporation, Wilmington
Pamela M. Murphy, 302-498-6944